Saphnelo recommended for EU approval for SLE
20 December 2021 07:00 GMT Saphnelo recommended for approval in the EU by CHMP for the treatment of patients with systemic lupus erythematosus Saphnelo is a first-in-class type I interferon receptor antibody shown to reduce overall disease activity in patients with systemic lupus erythematosus AstraZeneca's Saphnelo (anifrolumab) has been recommended for marketing authorisation in the European Union (EU) as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard